XKRX:005690 (Korea (the Republic of))
Â
Ordinary Shares
â‚©
4735.00
(-2.57%)
Nov 29
Business Description
Pharmicell Co Ltd
ISIN : KR7005690003
Share Class Description:
XKRX:005690: Ordinary SharesCompare
Compare
Traded in other countries / regions
005690.Korea IPO Date
1988-05-20Description
Pharmicell Co Ltd is a biotechnology company, engages in the manufacturing of biopharmaceutical medicines in South Korea. Its biopharmaceutical business engages in the development and manufacture of stem cell therapeutic drugs and stem cell-based cosmetics and others. Its products under development include mesenchymal stem cell products, such as Cellgram_AMI, a heart disease drug; Cellgram_IS and Cellgram_SCI, which are brain/nerve disorder drugs; Cellgram_Lung, a pulmonary disease drug; Cellgram_LC, a liver disease drug; and Cellgram_ED and Cellgram_CLI for the treatment of graft-versus-host disease, kidney transplant, impotence, and critical lower limb ischemia.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 16.41 | |||||
| Equity-to-Asset | 0.9 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | 0.07 | |||||
| Interest Coverage | 48.01 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 20.13 | |||||
| Beneish M-Score | -2.45 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 14.6 | |||||
| 3-Year EBITDA Growth Rate | 6.3 | |||||
| 3-Year EPS without NRI Growth Rate | -19.3 | |||||
| 3-Year FCF Growth Rate | -10.8 | |||||
| 3-Year Book Growth Rate | 12 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 33.46 | |||||
| 9-Day RSI | 39.06 | |||||
| 14-Day RSI | 40.84 | |||||
| 6-1 Month Momentum % | -12.54 | |||||
| 12-1 Month Momentum % | -18.41 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 9.01 | |||||
| Quick Ratio | 4.44 | |||||
| Cash Ratio | 2.28 | |||||
| Days Inventory | 191.54 | |||||
| Days Sales Outstanding | 53.04 | |||||
| Days Payable | 19.96 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shareholder Yield % | 4.09 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 29.91 | |||||
| Operating Margin % | 2.49 | |||||
| Net Margin % | 6.03 | |||||
| FCF Margin % | -3.26 | |||||
| ROE % | 4.2 | |||||
| ROA % | 3.63 | |||||
| ROIC % | 1.8 | |||||
| ROC (Joel Greenblatt) % | 8.73 | |||||
| ROCE % | 6.66 | |||||
| Years of Profitability over Past 10-Year | 5 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 83.09 | |||||
| PE Ratio without NRI | 83.09 | |||||
| PS Ratio | 4.96 | |||||
| PB Ratio | 3.45 | |||||
| Price-to-Tangible-Book | 3.69 | |||||
| Price-to-Operating-Cash-Flow | 49.57 | |||||
| EV-to-EBIT | 48.11 | |||||
| EV-to-EBITDA | 31.54 | |||||
| EV-to-Revenue | 4.85 | |||||
| EV-to-FCF | -150.74 | |||||
| Price-to-Projected-FCF | 5.5 | |||||
| Price-to-Median-PS-Value | 0.38 | |||||
| Price-to-Graham-Number | 3.69 | |||||
| Price-to-Net-Current-Asset-Value | 9.24 | |||||
| Price-to-Net-Cash | 300.06 | |||||
| Earnings Yield (Greenblatt) % | 2.08 | |||||
| FCF Yield % | -0.66 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Pharmicell Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil â‚©) | 56,589.91 | ||
| EPS (TTM) (â‚©) | 57 | ||
| Beta | 0.57 | ||
| Volatility % | 26.99 | ||
| 14-Day RSI | 40.84 | ||
| 14-Day ATR (â‚©) | 203.346668 | ||
| 20-Day SMA (â‚©) | 4936.25 | ||
| 12-1 Month Momentum % | -18.41 | ||
| 52-Week Range (â‚©) | 4300 - 8870 | ||
| Shares Outstanding (Mil) | 60 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Pharmicell Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Pharmicell Co Ltd Stock Events
| Event | Date | Price(â‚©) | ||
|---|---|---|---|---|
| No Event Data | ||||
Pharmicell Co Ltd Frequently Asked Questions
What is Pharmicell Co Ltd(XKRX:005690)'s stock price today?
The current price of XKRX:005690 is â‚©4735.00. The 52 week high of XKRX:005690 is â‚©8870.00 and 52 week low is â‚©4300.00.
When is next earnings date of Pharmicell Co Ltd(XKRX:005690)?
The next earnings date of Pharmicell Co Ltd(XKRX:005690) is .
Does Pharmicell Co Ltd(XKRX:005690) pay dividends? If so, how much?
Pharmicell Co Ltd(XKRX:005690) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers